Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
special 3 on DM AIFA

Special Commission Update No. 3 - Towards the reform of the governance of the Italian Medicines Agency and the Single Commission: where are we?

Update 20 November 2023 The extraordinary State-Regions Conference held on 16 November 2023, sanctioned the long-awaited agreement on the draft regulation of the ...
Read more "
article cover customer feedback

What they say about us, first results of our customer feedback request

As of January 2023, Pharma Value started, in cooperation with the soc. coop. Prospects, a work of evaluation and analysis ...
Read more "
EPA Congress on Orphan Drugs

Next steps for the revision of the Orphan Drug Regulation

The European Commission's official proposal is due to be published on 29 March 2023, but during the World Evidence, Pricing and ...
Read more "
Valeria Viola at OSSFOR report presentation

Proposed regulatory reform of 648/96 for fast access to orphan drugs

Rome, 31 January 2023. The following text summarises the speech by Valeria Viola, owner of Pharma Value, during the presentation of the VI ...
Read more "

Towards the reform of governance of the Italian Medicines Agency and the Single Committee

This is our English version of the analysis 'Towards the reform of governance of the Italian Medicines Agency and the Single Committee' ...
Read more "

Pharma Value Agenda 2023

Il tema dell’agenda Pharma Value 2023 è “soldi e valore”. L’agenda di quest’anno è il frutto di un lavoro collettivo di tutto ...
Read more "

Nomos Pharma Value SPECIAL No. 2: AIFA reform - scenario and next steps

Nomos e Pharma Value hanno sviluppato un documento di approfondimento per analizzare la riforma di AIFA definita nelle scorse settimane al Senato ...
Read more "
Ispor November 2022

Timing of access to drugs and advanced therapies (ATMP) for ultra-rare diseases

Martedì 29 novembre 2022 Ginevra Mastroianni, Institutional and Regulatory Affairs Specialist di Pharma Value, ha presentato all’8° Congresso Nazionale dell’ISPOR Italy – ...
Read more "
Master DRMKA Novara

15 years of the DRMKA Master, a TEDx on regulatory and market access activities

Venerdì 14 ottobre 2022 Valeria Viola ha partecipato con un TEDx all’evento organizzato dal professor Armando Genazzani per i 15 anni del ...
Read more "
en_GB